Search Results - "Davanlou, Masoud"

Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients by Yabe, Mariko, MD, PhD, Medeiros, L. Jeffrey, MD, Tang, Guilin, MD, PhD, Wang, Sa A., MD, P. Patel, Keyur, MD, PhD, Routbort, Mark, MD, PhD, Bhagat, Govind, MD, Bueso-Ramos, Carlos E., MD, PhD, Jorgensen, Jeffrey L., MD, PhD, Luthra, Rajyalakshmi, PhD, Chen, Weina, MD, PhD, Muzzafar, Tariq, MD, Kanagal-Shamanna, Rashmi, MD, Khoury, Joseph D., MD, Daneshbod, Yahya, MD, Davanlou, Masoud, MD, Li, Shaoying, MD, Young, Ken H., MD, PhD, Miranda, Roberto N., MD

“…Summary Hepatosplenic T-cell lymphoma (HSTCL) is a rare T-cell lymphoma commonly associated with cytopenias. The pathogenesis of cytopenias in patients with…”
Get full text

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents by Yang, H, Bueso-Ramos, C, DiNardo, C, Estecio, M R, Davanlou, M, Geng, Q-R, Fang, Z, Nguyen, M, Pierce, S, Wei, Y, Parmar, S, Cortes, J, Kantarjian, H, Garcia-Manero, G

“…Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2,…”
Get full text

Cancer in Iran 2008 to 2025: Recent incidence trends and short‐term predictions of the future burden by Roshandel, Gholamreza, Ferlay, Jacques, Ghanbari‐Motlagh, Ali, Partovipour, Elham, Salavati, Fereshteh, Aryan, Kimia, Mohammadi, Gohar, Khoshaabi, Mostafa, Sadjadi, Alireza, Davanlou, Masoud, Asgari, Fereshteh, Abadi, Hakimeh, Aghaei, Abbas, Ahmadi‐Tabatabaei, Seyed‐Vahid, Alizadeh‐Barzian, Kazem, Asgari, Abbasali, Asgari, Noorali, Azami, Soheyla, Cheraghi, Maria, Enferadi, Floria, Eslami‐Nasab, Masoumeh, Fakhery, Jila, Farahani, Mohsen, Farrokhzad, Solmaz, Fateh, Mansooreh, Ghasemi, Ali, Ghasemi‐Kebria, Fatemeh, Gholami, Hajar, Golpazir, Arash, Hasanpour‐Heidari, Susan, Hazar, Narjes, Hoseini‐Hoshyar, Hosein, Izadi, Mohsen, Jahantigh, Mahdi, Jalilvand, Ahmad, Jazayeri, Seyed‐Mehrdad, Kazemzadeh, Yasan, Khajavi, Maryam, Khalednejad, Maryam, Khanloghi, Marziyeh, Kooshki, Maryam, Madani, Amineh, Mirheidari, Mahdi, Mohammadifar, Hosein, Moinfar, Zeinab, Mojtahedzadeh, Yasaman, Morsali, Ali, Motidost‐Komleh, Rita, Mousavi, Tahereh, Narooei, Maboobeh, Nasiri, Mohammad, Niksiar, Sharareh, Pabaghi, Mehdi, Pirnejad, Habibollah, Pournajaf, Azadeh, Pourshahi, Gita, Rahnama, Amir, Rashidpoor, Bahman, Ravankhah, Zahra, Rezaei, Khadijeh, Rezaianzadeh, Abbas, Sadeghi, Gholamreza, Salehifar, Mohammad, Shahdadi, Athareh, Shahi, Mehraban, Sharifi‐Moghaddam, Farrokh, Sherafati, Roya, Soleimani, Ali, Soltany‐hojatabad, Maryam, Somi, Mohammad‐Hossein, Yadolahi, Sohrab, Yaghoubi‐Ashrafi, Majid, Zareiyan, Aliakbar, Poustchi, Hossein, Zendehdel, Kazem, Ostovar, Afshin, Janbabaei, Ghasem, Raeisi, Alireza, Weiderpass, Elisabete, Malekzadeh, Reza, Bray, Freddie

“…Policymakers require estimates of the future number of cancer patients in order to allocate finite resources to cancer prevention, treatment and palliative…”
Get full text

Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry by Roshandel, Gholamreza, Ghanbari-Motlagh, Ali, Partovipour, Elham, Salavati, Fereshteh, Hasanpour-Heidari, Susan, Mohammadi, Gohar, Khoshaabi, Mostafa, Sadjadi, Alireza, Davanlou, Masoud, Tavangar, Seyed-Mohammad, Abadi, Hakimeh, Asgari, Abasali, Behrooz, Mohamadreza, Cheraghi, Maria, Danechin, Leila, Dolatkhah, Roya, Enferadi, Floria, Esshaghi, soodabeh, Farahani, Mohsen, Farrokhzad, Solmaz, Fateh, Mansooreh, Vahedi, Siamak, Golpazir, Arash, Hasanzadeh, Mahdieh, Hazar, Narjes, Hoseini-hoshyar, Hosein, Izadi, Mohsen, Jafarnia, Ali, Jahantigh, Mahdi, Jalilvand, Ahmad, Jazayeri, Mehrdad, Joola, Parvin, Kazemzadeh, Yasan, Khalednejad, Maryam, Kooshki, Maryam, Madani, Amineh, Malekpour-afshar, Reza, Bayat, Amir-Hossein, Moinfar, Zeinab, Mohamadifar, Hosein, Mohamadzadeh, Gholamhasan, Motidost-komleh, Rita, Narooei, Mahboobeh, Niksiar, Sharareh, Pirnejad, Habibollah, Poornajaf, Azadeh, Pourshahi, Gita, Rahnama, Amir, Rashidpour, Bahman, Ravankhah, Zahra, Rezaei, Khadijeh, Rezaeianzadeh, Abbas, Sadeghi, Gholamreza, Shahdadi, Athar, Shahi, Mehraban, Sharafi, Zahra, Sharifi-moghadam, Farroq, Soleimani, Ali, Soltany-hojatabad, Maryam, Tahmasebi, Zeinab, Yadolahi, Sohrab, Yaghoubi-ashrafi, Majid, Zandian, Hamed, Zareiyan, Aliakbar, Poustchi, Hossein, Zendehdel, Kazem, Ostovar, Afshin, Janbabaei, Ghasem, Reisi, Alireza, Malekzadeh, Reza

“…•The first report of Iranian National Population-based Cancer Registry was presented.•Our results showed that Iran is a medium-risk area for incidence of…”
Get full text

Bladder Cancer Incidence in Iran: Results of the Iranian National Population-Based Cancer Registry from 2014 to 2016 by Ostovar, Afshin

“…Purpose: Bladder cancer is a common cancer in the world with the highest rates in Southern and Western Europe, North America, and Western Asia. It imposes a…”
Get full text

Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor–α inhibitor therapy and literature review by Yabe, Mariko, Medeiros, L. Jeffrey, Daneshbod, Yahya, Davanlou, Masoud, Bueso-Ramos, Carlos E, Moran, Elisa J, Young, Ken H, Miranda, Roberto N

“…Abstract Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive extranodal T-cell lymphoma that can arise in patients with underlying immune disorders…”
Get full text

Hepatosplenic T-cell Lymphoma Arising in Patients with Immunodysregulatory Disorders: A Study of 7 Patients Who Did Not Receive TNF-α Inhibitor Therapy and Literature Review by Yabe, Mariko, Medeiros, L. Jeffrey, Daneshbod, Yahya, Davanlou, Masoud, Bueso-Ramos, Carlos E., Moran, Elisa J., Young, Ken H., Miranda, Roberto N.

“…Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive extranodal T-cell lymphoma that can arise in patients with underlying immune disorders. Others…”
Get full text

Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS) by Yang, Hui, Bueso-Ramos, Carlos E., DiNardo, Courtney D., Estecio, Marcos R, Davanlou, Masoud, Geng, Qi-Rong, Fang, Zhihong, Nguyen, Martin, Pierce, Sherry, Wei, Yue, Parmar, Simrit, Cortes, Jorge E., Kantarjian, Hagop M., Garcia-Manero, Guillermo

“…The pathogenesis of MDS is multifactorial including both cell intrinsic alterations, such as mutations, and cell extrinsic stimuli such as immune deregulation…”
Get full text